DePuy ASR Lawsuit Update: Bernstein Liebhard LLP Reports on Latest Developments Pertaining to DePuy ASR Hip Recall Settlement
New York, New York (PRWEB) March 06, 2014 -- The federal court overseeing thousands of DePuy ASR hip lawsuits (http://www.consumerinjurylawyers.com/DePuy/) continues to prepare for the implementation of the settlement program announced last November, Bernstein Liebhard LLP reports. According to an Order issued in the U.S. District Court, Northern District of Ohio on March 3, the Court has granted a motion filed by plaintiffs’ attorneys to modify the Common Benefit Order, following a hearing on February 26, 2014, at which time no objections were raised (In re: DePuy Orthopaedics, Inc. ASR Hip Implant Products Liability Litigation – MDL 2197)
“Our Firm is representing numerous DePuy ASR lawsuit clients who are eligible to participate in the settlement program. We look forward to more progress in this matter in the coming months,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free legal evaluations to individuals who allegedly experienced metallosis, chronic pain, disability, premature hip implant failure, and other serious complications allegedly related to devices included in the DePuy ASR recall.
DePuy ASR Recall Settlement
The DePuy ASR recall settlement was announced in the Northern District of Ohio on November 19, 2013. Under the terms of the settlement agreement, eligible claimants would be entitled to a base award of $250,000.That award could be reduced, however, depending on certain other factors, including a claimant’s prior medical history. Other circumstances could entitle plaintiffs to a supplemental award if they, for example, required multiple revision surgeries, or if they experience “certain extraordinary injuries” in the future.
According to a report from The New York Times, the settlement could resolve some 8,000 of the 12,000 DePuy ASR lawsuits currently pending against Johnson & Johnson and its DePuy Orthopaedics unit. Those plaintiffs who are not eligible to participate, as well as those who select to opt out, will still be entitled to pursue product liability claims against the companies.*
DePuy ASR hip implant recipients who allegedly suffered serious and debilitating complications, including metallosis (metal ion poisoning), pseudotumor formation, and premature device failure, may be entitled to compensation. To learn more about the DePuy ASR recall, please visit Bernstein Liebhard LLP’s website, or call 800-511-5092 to arrange for a free, no-obligation case review.
*nytimes.com/2013/11/20/business/johnson-johnson-to-offer-2-5-billion-hip-device-settlement.html?_r=0, New York Times, November 19, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.consumerinjurylawyers.com
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Pradaxa Lawsuit Information Center, http://www.pradaxalawsuithelp.com/, +1 800-511-5092, [email protected]
Share this article